Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
1. A metal-bisphosphonate nanoparticle comprising a core comprising:
(a) M 1 , wherein M 1 is a multivalent metal ion; and
(b) a bisphosphonate, wherein the bisphosphonate comprises a metal complex having the formula M 2 L x , wherein x is an integer of 2 or greater, M 2 is a second metal ion, and wherein each L is a metal ion ligand, further wherein at least two L are phosphonate group-containing metal ion ligands, wherein the phosphonate group of each of said phosphonate group-containing metal ion ligands is available to coordinate to multivalent metal ion M 1 and wherein the at least two phosphonate group-containing metal ion ligands are each coordinated to M 2 via a coordinative bond between M 2 and an oxygen atom of the phosphonate group-containing ligand.
2. The metal-bisphosphonate nanoparticle of claim 1 , wherein the bisphosphonate comprises at least one metal ion ligand L that does not contain a phosphonate group.
3. The metal-bisphosphonate nanoparticle of claim 2 , wherein the bisphosphonate comprises a metal ion ligand selected from the group consisting of halo, NH 3 , alkylamino, hydroxyl, alkoxyl, diol, and diamine.
4. The metal-bisphosphonate nanoparticle of claim 2 , wherein the bisphosphonate comprises a metal ion ligand that does not comprise a phosphonate group and wherein said ligand is a metal ion ligand other than NH 3 or diamine.
5. The metal-bisphosphonate nanoparticle of claim 1 , wherein x is 5 or 6.
6. The metal-bisphosphonate nanoparticle of claim 1 , wherein two L are NH 3 .
7. The metal-bisphosphonate nanoparticle of claim 1 , wherein two L are halo.
8. The metal-bisphosphonate nanoparticle of claim 1 , wherein at least one L is a diamine.
9. The metal-bisphosphonate nanoparticle of claim 1 , further wherein the oxygen atom of the phosphonate group-containing ligand coordinatively bound to M 2 is covalently bound to a carbon atom of the phosphonate group-containing ligand.
10. The metal-bisphosphonate nanoparticle of claim 9 , wherein the carbon atom of the phosphonate group-containing ligand is a carbon atom of a carbonyl group.
11. A metal-bisphosphonate nanoparticle comprising a core comprising:
(a) M 1 , wherein M 1 is a multivalent metal ion; and
(b) a bisphosphonate, wherein the bisphosphonate comprises a metal complex having the formula M 2 L x , wherein x is an integer of 2 or greater, M 2 is a second metal ion, and wherein each L is a metal ion ligand, further wherein at least two L are phosphonate group-containing metal ion ligands, wherein the phosphonate group of each of said phosphonate group-containing metal ion ligands is available to coordinate to multivalent metal ion M 1 and wherein each of the phosphonate group-containing metal ion ligands is coordinated to M 2 via a coordinative bond between M 2 and an oxygen atom of the phosphonate group-containing ligand, wherein said oxygen atom of the phosphonate group-containing ligand is covalently bound to a carbon atom of a thiocarbonyl group.
12. The metal-bisphosphonate nanoparticle of claim 1 , wherein the bisphosphonate is prepared by reacting a metal complex comprising two hydroxyl ligands with a reagent selected from the group consisting of diethoxyphosphinyl isocyanate, diethoxyphosphinyl isothiocyanate, a diethyoxyphosphinyl-containing carboxylic anhydride, and a diethoxyphosphinyl-containing acyl chloride.
13. The metal-bisphosphonate nanoparticle of claim 1 , wherein M 2 is a platinum ion.
14. The metal-bisphosphonate nanoparticle of claim 1 , wherein M 1 is Zn 2+ .
15. The metal-bisphosphonate nanoparticle of claim 1 , wherein the nanoparticle further comprises one or more coating agents or layers surrounding at least a portion of an outer surface of the core.
16. The metal-bisphosphonate nanoparticle of claim 15 , wherein the nanoparticle comprises at least one lipid coating layer or agent.
17. The metal-bisphosphonate nanoparticle of claim 15 , wherein one or more coating agents or layers comprise a targeting moiety or a passivating moiety.
18. A pharmaceutical composition comprising a metal-bisphosphonate nanoparticle of claim 1 and a pharmaceutically acceptable carrier.
19. A method of treating cancer in a subject in need of treatment thereof, wherein the method comprises administering to said subject an effective amount of a metal-bisphosphonate nanoparticle of claim 1 .